ARDXHealthcare · BiotechnologyThe 11 Wall Street analysts covering Ardelyx, Inc. hold a median 12-month price target of $14 — +312.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 8 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Ardelyx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (98): The business earns solid, repeatable profits on what it owns.
Momentum (15): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ARDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +312.8% from it.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | Wedbush | Reiterates | Outperform | $9.00 |
| 18 Aug 2026 | Wedbush | Reiterates | Outperform | $9.00 |
| 17 Aug 2026 | Piper Sandler | Maintains | Overweight | $16 → $15 |
| 10 Aug 2026 | Citigroup | Maintains | Buy | $14 → $11 |
| 10 Aug 2026 | Citigroup | Maintains | Buy | — |
| 7 Aug 2026 | BTIG | Maintains | Buy | $17 → $14 |
| 7 Aug 2026 | BTIG | Maintains | Buy | — |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | $13 → $10 |
| 16 June 2026 | Ladenburg Thalmann | Assumes | Buy | $16 |
| 23 Feb 2026 | Wedbush | Reiterates | Outperform | — |
| 20 Feb 2026 | BTIG | Reiterates | Buy | — |
| 20 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Jan 2026 | BTIG | Reiterates | Buy | — |
| 21 Jan 2026 | Wedbush | Maintains | Outperform | — |
| 9 Jan 2026 | BTIG | Maintains | Buy | — |
| 9 Jan 2026 | Citigroup | Maintains | Buy | — |
| 9 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 4 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 3 Nov 2025 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARDX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Ardelyx, Inc. returned −35.4% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 54% of US stocks
Cheaper than 18% of US stocks
Cheaper than 91% of US stocks
Higher than 73% of US stocks
Higher than 62% of US stocks
Higher than 98% of US stocks
Higher than 24% of US stocks
Higher than 18% of US stocks
Higher than 25% of US stocks
Higher than 33% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ardelyx, Inc. has a market value of $841.7M and an enterprise value of $825.5M.
Revenue in the twelve months to 30 June 2026: $450.9M. The latest quarter grew 23.8% year on year.
Net income over the same four quarters: −$55.7M, a −12.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.22.
Free cash flow in the twelve months to 30 June 2026: −$17.9M.
Trailing P/E: −12.4×; forward P/E: 11.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ardelyx, Inc. employs 489 people — $922K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ardelyx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research added ARDX, along with ACH and DPRO, to its Zacks Rank #5 (Strong Sell) List on October 9, 2026.
Why it matters — ARDX watchers may note the company’s inclusion on the list in Zacks’ October 9 update.
Schall, Brown & Schwartz LLP announced a class action lawsuit against Ardelyx, alleging violations of federal securities laws. The firm encouraged shareholders who purchased ARDX shares during the specified class period to contact it about possible lead plaintiff appointments.
Why it matters — The lawsuit and lead plaintiff outreach concern Ardelyx shareholders and the company’s securities-related legal matters.
Rosen Law Firm reminded Ardelyx common-stock purchasers during January 13, 2025–August 6, 2026 of a November 16, 2026 lead plaintiff deadline in a securities fraud lawsuit. The firm said eligible purchasers may be entitled to compensation through a contingency fee arrangement without out-of-pocket fees or costs.
Why it matters — ARDX investors who purchased shares during the stated class period may wish to note the lawsuit’s lead plaintiff deadline.
Zacks Investment Research added ARDX to its Zacks Rank #5 (Strong Sell) List on October 7, 2026, along with LUV and COLL.
Why it matters — ARDX watchers may note the company's inclusion on the Zacks Strong Sell list.
The 11 Wall Street analysts covering Ardelyx, Inc. have a median 12-month price target of $14, with estimates ranging from $8 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Ardelyx, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ardelyx, Inc. 49 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Ardelyx, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +312.8% from the last close, and Ticker Nerd's factor model ranks Ardelyx, Inc. 49 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ardelyx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $18 over the next 12 months.
Ardelyx, Inc. returned -35.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ardelyx Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal and cardiorenal diseases.
The most recent item we track (Zacks Investment Research, 9 Oct 2026): "New Strong Sell Stocks for October 9th". Zacks Investment Research added ARDX, along with ACH and DPRO, to its Zacks Rank #5 (Strong Sell) List on October 9, 2026.
Ardelyx Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal and cardiorenal diseases. The company’s current portfolio centers on tenapanor-based therapies, including IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx also works on therapies for related metabolic and kidney disorders, using its gut-targeted science platform to address conditions that often have limited treatment options. Headquartered in Waltham, Massachusetts, and founded in 2007, Ardelyx serves patients in the United States through direct commercialization and supports broader reach through select partnerships. The company operates in the biotechnology and specialty pharmaceuticals markets, where it contributes prescription treatments designed for chronic, specialist-managed conditions.
CEO Mr. Michael G. Raab · 489 employees · United States · https://www.ardelyx.com
